Sino Biopharmaceutical (OTCMKTS:SBMFF) Reaches New 12-Month High at $1.98

Share on StockTwits

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF)’s stock price reached a new 52-week high on Monday . The company traded as high as $1.98 and last traded at $1.85, with a volume of 570 shares. The stock had previously closed at $1.91.

Several research firms have recently commented on SBMFF. ValuEngine raised Sino Biopharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, April 2nd. Sanford C. Bernstein raised Sino Biopharmaceutical from an “underperform” rating to a “market perform” rating in a report on Tuesday, May 12th. Zacks Investment Research downgraded Sino Biopharmaceutical from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. Finally, Goldman Sachs Group raised Sino Biopharmaceutical from a “neutral” rating to a “buy” rating in a report on Thursday, March 19th.

The company has a quick ratio of 2.01, a current ratio of 2.17 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average price of $1.67 and a 200 day moving average price of $1.49.

About Sino Biopharmaceutical (OTCMKTS:SBMFF)

Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules.

Read More: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for Sino Biopharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

InnerWorkings  & CardioGenics  Head-To-Head Contrast
InnerWorkings & CardioGenics Head-To-Head Contrast
Head to Head Analysis: Castlight Health  vs. JMU Ltd-
Head to Head Analysis: Castlight Health vs. JMU Ltd-
Financial Comparison: ChampionX  vs. Ecosphere Technologies
Financial Comparison: ChampionX vs. Ecosphere Technologies
Financial Survey: Mimecast  versus Cloudflare
Financial Survey: Mimecast versus Cloudflare
Analyzing Curaegis Technologies  & American Axle & Manufact.
Analyzing Curaegis Technologies & American Axle & Manufact.
Bloom Energy Corp  Expected to Post Quarterly Sales of $168.93 Million
Bloom Energy Corp Expected to Post Quarterly Sales of $168.93 Million


© 2006-2020 Ticker Report